Clinical and Institutional Practice Update: Optimization of Anti-Xa Lab Test Utilization Across Care Centers
Perhaps more than any other area of clinical medicine, anticoagulation management laboratory data are evaluated hourly by healthcare systems in the inpatient setting and daily in the outpatient setting to provide efficacy, safety, and markers of clinical success for drugs and disease states relating to embolic disease. These laboratory data provide answers that in their absence, or a failure of understanding, can result in patient harm or death. Accordingly, laboratory staff, pharmacists, hematologists, and pathologists supervising these efforts need concise, evidence-based, expert-endorsed information upon which to predicate their ability to understand and provide the same. This continuing education activity will discuss these issues, allowing participants to provide clinical laboratory data with the highest integrity and service to their patients.
- Describe differences between unfractionated heparin (UFH), low-molecular-weight-heparin (LMWH) and direct-oral anticoagulants (DOACs) and impact on laboratory monitoring
- Identify advantages and disadvantages of surrogate markers to monitor and measure efficacy of UFH LMWH and DOACs, focusing on reference ranges and limitations of the traditional surrogate markers and benefit of anti-Xa monitoring
- Present management strategies for appropriate use of anti-Xa heparin level determinations
- Highlight case studies featuring situations for which direct oral anticoagulant measurement assisted with patient management
LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety. CE credits are available for this webinar up to 2 years from the date of the live broadcast